Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

Ayala Pharmaceuticals logo

About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.50
$0.50
50-Day Range
$0.38
$0.58
52-Week Range
$0.36
$7.31
Volume
N/A
Average Volume
76,300 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Remove Ads
Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AYLA Stock News Headlines

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
ADXS Ayala Pharmaceuticals, Inc.
See More Headlines

AYLA Stock Analysis - Frequently Asked Questions

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.12. The firm earned $0.63 million during the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 182.13% and a negative net margin of 2,341.69%.

Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include HubSpot (HUBS), Netflix (NFLX), ForgeRock (FORG), Bank of America (BAC), ConocoPhillips (COP) and Diamondback Energy (FANG).

Company Calendar

Last Earnings
11/15/2021
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AYLA
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,250,000.00
Net Margins
-2,341.69%
Pretax Margin
-2,298.60%

Debt

Sales & Book Value

Annual Sales
$3.51 million
Price / Cash Flow
N/A
Book Value
$2.45 per share
Price / Book
0.21

Miscellaneous

Free Float
14,287,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
1.98
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AYLA) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners